STOCK TITAN

Xilio Therapeutics (XLO) 424B Filings

XLO NASDAQ

Here are the 424B prospectus supplements from Xilio Therapeutics, Inc. (XLO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow XLO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XLO filings page.

Rhea-AI Summary

Xilio Therapeutics is offering pre-funded warrants to purchase up to 74,780,300 shares of common stock at $0.5349 per warrant, each exercisable for one share at an exercise price of $0.0001. Gross proceeds are expected to be about $40.0 million, with approximately $37.1 million in net proceeds after fees and expenses.

As of December 31, 2025, Xilio had $137.5 million in cash and cash equivalents, and it expects existing cash plus this financing to fund operations through the end of 2027. The company warns that purchasers will experience immediate dilution, estimating a $0.2978 per-share dilution relative to the pro forma as adjusted net tangible book value.

The pre-funded warrants are subject to beneficial ownership limits of 4.99%, 9.99% or 19.99%, will not be listed on any exchange, and may be exercised on a cash or cashless basis. Xilio also highlights a planned February 23, 2026 stockholder vote on a reverse stock split to regain Nasdaq compliance, noting the split may not achieve the intended listing effects and could negatively impact the share price.

Rhea-AI Summary

Xilio Therapeutics is updating its stock sale program to offer up to an aggregate of $9,500,000 of common stock through its existing sales agreement with Leerink Partners LLC. This reduces the previous capacity of up to $50,000,000 under the earlier prospectus. The shares may be sold from time to time under the Form S-3 shelf, and as of February 10, 2026, the last reported sale price of the common stock on The Nasdaq Capital Market under the symbol “XLO” was $0.5415 per share.